Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
This review describes the haemodynamic and electrophysiologic properties of diltiazem and shows how these effects may, in some clinical situations, favour the choice of this drug as an antianginal and antiarrhythmic agent. Compared to nifedipine and verapamil, diltiazem has the distinct advantage of being a negative chronotropic agent and thus has the potential of leading to a greater reduction in myocardial oxygen consumption; it does not affect cardiac output, left ventricular end diastolic pressure, and ejection fraction in patients with an adequately preserved left ventricular function; finally, it possesses a longer duration of action and fewer side effects, even at relatively high calcium entry blocking doses, than the other major calcium entry blockers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0773.1985.tb03571.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!